

Order information

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
05599261 190	Albumin BCP 225 tests	System-ID 07 7471 5 Roche/Hitachi cobas c 311, cobas c 501/502
10759350 190	Calibrator f.a.s. (12 x 3 mL)	Code 401
10759350 360	Calibrator f.a.s. (12 x 3 mL, for USA)	Code 401
12149435 122	Precinorm U plus (10 x 3 mL)	Code 300
12149435 160	Precinorm U plus (10 x 3 mL, for USA)	Code 300
12149443 122	Precipath U plus (10 x 3 mL)	Code 301
12149443 160	Precipath U plus (10 x 3 mL, for USA)	Code 301
10171743 122	Precinorm U (20 x 5 mL)	Code 300
10171735 122	Precinorm U (4 x 5 mL)	Code 300
10171778 122	Precipath U (20 x 5 mL)	Code 301
10171760 122	Precipath U (4 x 5 mL)	Code 301
10557897 122	Precinorm Protein (3 x 1 mL)	Code 302
10557897 160	Precinorm Protein (3 x 1 mL, for USA)	Code 302
11333127 122	Precipath Protein (3 x 1 mL)	Code 303
11333127 160	Precipath Protein (3 x 1 mL, for USA)	Code 303
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

English

System information

For **cobas c** 311/501 analyzers:

ALBP: ACN 760

For **cobas c** 502 analyzer:

ALBP: ACN 8760

Intended use

In vitro test for the quantitative determination of albumin in human serum and plasma on Roche/Hitachi **cobas c** systems.

Summary

Albumin constitutes about 60 % of the total serum protein in normal, healthy individuals. Unlike most other serum proteins, albumin serves a number of functions, which include transport of large insoluble organic anions (e.g., long chain fatty acids and bilirubin), binding of toxic heavy metal ions, transport of excess quantities of poorly soluble hormones (eg, cortisol, aldosterone, and thyroxine), maintenance of serum osmotic pressure, and provision of a reserve store of protein.

In 1953, Bracken and Klotz described the first useful dye-binding technique for measuring albumin in serum; albumin added to a solution of methyl orange buffered at pH 3.5 was found to bind and effectively remove some of the pink anion, resulting in a decrease in absorbance at 550 nm.¹ Other dyes successfully used to bind and quantitate serum albumin include 2-(4-hydroxy-azobenzene) benzoic acid (HABA), bromocresol green (Dumas procedure)², and bromocresol purple. Of these, bromocresol purple offers increased sensitivity. Although bromocresol purple is structurally similar to bromocresol green, its pH color change interval is higher (5.2-6.8 for BCP as opposed to 3.8-5.4 for BCG), thus reducing the number of weak electrostatic dye/protein interactions. The Albumin/BCP procedure eliminates many nonspecific reactions with other serum proteins as a result of the increased reagent pH. In addition, use of a sample blank removes background spectral interferences not completely removed by bichromatic analysis.

Test principle

Colorimetric test

At the reaction pH, BCP binds selectively with albumin, causing a color change that is measured photometrically.

Reagents - working solutions

R1 Buffer; preservatives; surfactants

R2 BCP: 526 µmol/L; buffer; preservatives; surfactant

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

Reagent handling

Ready for use

Storage and stability

ALB BCP

Shelf life at 15-25 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

4 weeks

Diluent NaCl 9 %

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

12 weeks

Specimen collection and preparation

If possible, the patient should be recumbent for at least 1 hour preceding specimen collection. Erect posture causes a redistribution of body fluids, increasing the serum albumin concentration.³

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.
Serum.

Plasma: Li-heparin and K₂-EDTA plasma.

Do not use citrate or oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability: ⁴	2.5 months at 20-25 °C
	5 months at 4-8 °C
	4 months at -20 °C

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

See "Order information" section

General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma

cobas c 311 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 6-26		
Wavelength (sub/main)	700/600 nm		
Reaction direction	Increase		
Units	g/L (μmol/L, g/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	115 μL	–	
R2	70 μL	–	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	2 μL	–	–
Decreased	4 μL	15 μL	135 μL
Increased	2 μL	–	–

cobas c 501 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-28		
Wavelength (sub/main)	700/600 nm		
Reaction direction	Increase		
Units	g/L (μmol/L, g/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	115 μL	–	
R2	70 μL	–	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)

		Sample	Diluent (NaCl)
Normal	2 μL	–	–
Decreased	4 μL	15 μL	135 μL
Increased	2 μL	–	–

cobas c 502 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-28		
Wavelength (sub/main)	700/600 nm		
Reaction direction	Increase		
Units	g/L (μmol/L, g/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	115 μL	–	
R2	70 μL	–	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	2 μL	–	–
Decreased	4 μL	15 μL	135 μL
Increased	4 μL	–	–

Calibration

Calibrators	S1: H ₂ O S2: C.f.a.s.
Calibration mode	Linear
Calibration frequency	2-point calibration • after reagent lot change • as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the ERM DA470k reference preparation.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	g/L x 15.2 = μmol/L
	μmol/L x 0.0658 = g/L
	g/L x 0.1 = g/dL

Limitations – interference

Criterion: Recovery within ± 10 % of initial values at an albumin concentration of 35 g/L (532 μmol/L).

Icterus:⁵ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 μmol/L or 60 mg/dL).

Hemolysis:⁵ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 μmol/L or 1000 mg/dL).

Lipemia (Intralipid):⁵ No significant interference up to an L index of 1000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{6,7}

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.⁸

The absorptivity of the dye-albumin complex differs for albumin obtained from different species. Materials used for the standardization and control of test results must be of human origin or must have albumin values assigned using an albumin BCP procedure.

Negative bias of approximately 10 % has been observed on samples from patients undergoing hemodialysis. Samples from patients with elevated serum creatinine levels, or undergoing treatment with peritoneal dialysis, were unaffected.⁹

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Colorimetric methods used for the determination of Albumin may lead to falsely elevated test results in patients suffering from renal failure or insufficiency due to interference with other proteins. Immunoturbidimetric methods are less affected.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

2-100 g/L (30.4-1520 µmol/L)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:5 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 5.

Lower limits of measurement

Lower detection limit of the test

2 g/L (30.4 µmol/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values^{10,11}

Adults	35-52 g/L	532-790 µmol/L	3.5-5.2 g/dL
Newborn 0-4 days	28-44 g/L	426-669 µmol/L	2.8-4.4 g/dL
Children 4 days-14 years	38-54 g/L	578-821 µmol/L	3.8-5.4 g/dL
14-18 years	32-45 g/L	486-684 µmol/L	3.2-4.5 g/dL

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Roche has not evaluated reference ranges in a pediatric population.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Repeatability	Mean	SD	CV
	g/L (µmol/L)	g/L (µmol/L)	%

Precinorm U	31.7 (482)	0.2 (3)	0.7
Precipath U	29.1 (442)	0.4 (6)	1.3
Human serum 1	36.6 (556)	0.3 (5)	0.8
Human serum 2	44.6 (678)	0.3 (5)	0.7

Intermediate precision	Mean g/L (µmol/L)	SD g/L (µmol/L)	CV %
Precinorm U	31.0 (471)	0.3 (5)	1.1
Precipath U	28.6 (435)	0.3 (5)	1.0
Human serum 1	36.2 (550)	0.4 (6)	1.1
Human serum 2	44.0 (669)	0.6 (9)	1.3

Method comparison

Albumin values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi MODULAR P analyzer (x).

Sample size (n) = 75

Passing/Bablok ¹²	Linear regression
y = 0.978x + 1.03 g/L	y = 0.977x + 1.11 g/L
τ = 0.967	r = 0.999

The sample concentrations were between 8.6 and 91.8 g/L (131 and 1395 µmol/L).

References

- Bracken JS, Klotz IM. A simple method for the rapid determination of serum albumin. *Am J Clin Pathol* 1953;23(10):1055-1058.
- Dumas BT, Biggs HG. *Standard Methods of Clinical Chemistry*. Cooper GA (ed). New York, NY: Academic Press, Inc 1972;7:175-188.
- Winsten S. *Standard Methods of Clinical Chemistry* 1965;5:1.
- Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2. Jan. 2002.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". *Eur J Clin Chem Clin Biochem* 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.
- Beyer C, Boekhout M, van Iperen H. Bromocresol Purple Dye-binding and Immunoturbidimetry for Albumin Measurement in Plasma or Serum of Patients with Renal Failure. *Clin Chem* 1994;40(5):844-845.
- Burtis CA, Ashwood ER, eds. *Tietz Fundamentals of Clinical Chemistry*, 5th ed. Pa: WB Saunders Co 2001;962.
- Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). *Eur J Clin Chem Clin Biochem* 1996;34:517-520.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

ALBP

Albumin BCP



Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, PRECICONTROL, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2017, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com



Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336